Moderna is starting Clinical I trials for a new HIV Vaccine using new tools i.e., immunogens and platforms. Researchers have developed both a primary vaccine and a booster to deliver HIV immunogens (molecules that elicit an immune response) via mRNA. Ideally, this process will induce B cells (white blood cells) which create neutralizing antibodies that can neutralize the virus. Phase I of the trial will enroll 56 healthy, HIV-negative adult participants at GWU and three additional sites: Hope Clinic of Emory Vaccine Center in Atlanta; Fred Hutchinson Cancer Research Center in Seattle; and the University of Texas-Health Science Center at San Antonio. Of the volunteers, 48 will receive one or two doses of the mRNA vaccine, and 32 also will receive the booster. The remaining eight will receive just the booster.
HIV mRNA Vaccine – Clinical I Trails
Moderna is starting Clinical I trials for a new HIV Vaccine using new tools i.e., immunogens and platforms. Researchers have developed both a primary vaccine and a booster to deliver HIV immunogens (molecules that elicit an immune response) via mRNA. Ideally, this process will induce B cells (white blood cells) which create neutralizing antibodies that can neutralize the virus. Phase I of the trial will enroll 56 healthy, HIV-negative adult participants at GWU and three additional sites: Hope Clinic of Emory Vaccine Center in Atlanta; Fred Hutchinson Cancer Research Center in Seattle; and the University of Texas-Health Science Center at San Antonio. Of the volunteers, 48 will receive one or two doses of the mRNA vaccine, and 32 also will receive the booster. The remaining eight will receive just the booster.
Source: https://abcnews.go.com/Health/moderna-launches-clinical-trial-hiv-vaccine-mrna-technology/story?id=82510807